These findings agree with the increased CCL5 mRNA expression observed in liver samples from patients with fibrotic NASH compared with subjects with simple steatosis, suggesting that CCL5 expression is a marker of fibrotic liver disease (141). The gene discussed is CCL5; the disease is metabolic dysfunction-associated steatohepatitis.